Investigation on the Anti-Cancer Effects of HER2-Targeted CAR-T Cells Engineered Using the PiggyBac Transposon System

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is effective against blood cancers but faces challenges in solid tumors, including off-target effects.
• Optimizing CAR-T cells for enhanced antigen binding is crucial for improving their efficacy against solid tumors.
• Human Endothelial Growth Factor Receptor 2 (HER2) is a target in certain solid tumors, necessitating targeted therapeutic strategies.

Purpose of the Study:

• To compare the efficacy and safety of two third-generation CAR-T cells targeting HER2.
• To evaluate CAR-T cells constructed with a classical anti-HER2 scFv from trastuzumab versus a novel anti-HER2-13 scFv.
• To assess CAR-T cell phenotypes, in vitro, and in vivo functions using PiggyBac transposon-mediated gene transfer.

Main Methods:

• Construction of third-generation CAR-T cells using two distinct anti-HER2 single-chain variable fragments (scFvs).
• Utilized PiggyBac transposon-mediated gene transfer for CAR-T cell transduction.
• Compared phenotypes, expansion, and in vitro/in vivo antitumor activity of the two CAR-T cell types in a HER2+ breast tumor xenograft model.

Main Results:

• Both HER2-targeted CAR-T cell types demonstrated significant antitumor activity.
• Anti-HER2-13 CAR-T cells exhibited superior target specificity and slightly enhanced efficacy in vivo.
• No evident off-target toxicity was observed with anti-HER2-13 CAR-T cells in the xenograft model.

Conclusions:

• Anti-HER2-13 CAR-T cells represent a potentially safer and more effective option for HER2-targeted cancer therapy.
• These findings support the development of novel CAR-T cell designs for improved solid tumor treatment.
• Further research into optimizing CAR-T cell specificity is warranted for broader clinical application.